Avalyn 药
AVLN
23.66
-0.98
-3.98%
Avalyn 药
US · AVLN
#3161 按市值排名
上市于 2026
23.66
-0.98
-3.98%
实时 - 追踪5344个代码 - 心跳于371秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
增持
- 最近一期（2026/Q3）披露持股的机构数量增加了5家。
- 机构持股总比例上升了2.9个百分点。
机构持股
- 机构持股比例
- 108.86% +2.95pp
- 机构数量
- 117 +5
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
VC/PE Fund50.36%
Mutual Fund37.90%
Hedge Fund19.03%
Public Company0.81%
Sovereign Wealth Fund0.62%
主要股东 截至 2026-06-30
Novo Holdings A/S
8.76% · 3.88M 股
FMR
8.01% · 3.55M 股
T. Rowe Price Group, Inc.
7.53% · 3.34M 股
SR One Capital Management, LP
7.46% · 3.31M 股
Perceptive Advisors LLC
6.03% · 2.68M 股
Montanova Capital, LLC
5.65% · 2.50M 股
F Prime, Inc.
5.15% · 2.28M 股
Impresa Management LLC
5.15% · 2.28M 股
NVP Associates, LLC
5.12% · 2.27M 股
Wellington Management Group
4.97% · 2.20M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪29份申报 · 16次买入 · 0次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Wellington Management Group | -- | -- |
| Novo Holdings A/S | -- | -- |
| Douglas Carlson | CFO & Chief Business Officer | -- |
| Heather Turner | Independent Chairperson | -- |
| Lyn Baranowski | Chief Executive Officer | -- |
| Kathryn Haviland | Independent Director | -- |
| Impresa Management LLC | -- | -- |
| Jon Congleton | Independent Director | -- |
| Robert Meyer | Director | -- |
| Erin Lavelle | Independent Director | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-14 | Robert Meyer | Director | Other Derivative Acquisition | +31,182 | $34.28 |
| 2026-04-30 | Wellington Management Group | -- | Derivative Exercise and Retained | +1,275,486 | -- |
| 2026-04-30 | Novo Holdings A/S | -- | Private Acquisition | +555,555 | $18.00 |
| 2026-04-30 | Novo Holdings A/S | -- | Derivative Exercise and Retained | +3,327,734 | -- |
| 2026-04-30 | Impresa Management LLC | -- | Derivative Exercise and Retained | +2,284,535 | -- |
| 2026-04-30 | SR One Capital Management, LP | -- | Private Acquisition | +555,555 | $18.00 |
| 2026-04-30 | SR One Capital Management, LP | -- | Derivative Exercise and Retained | +2,753,094 | -- |
| 2026-04-29 | Douglas Carlson | CFO & Chief Business Officer | Other Derivative Acquisition | +211,975 | $18.00 |
| 2026-04-29 | Erin Lavelle | Independent Director | Other Derivative Acquisition | +26,978 | $18.00 |
| 2026-04-28 | Novo Holdings A/S | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-04-28 | Douglas Carlson | CFO & Chief Business Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-04-28 | Heather Turner | Independent Chairperson | Other Derivative Acquisition | +26,978 | $18.00 |
| 2026-04-28 | Heather Turner | Independent Chairperson | Initial Statement of Beneficial | 0 | -- |
| 2026-04-28 | Lyn Baranowski | Chief Executive Officer | Other Derivative Acquisition | +501,033 | $18.00 |
| 2026-04-28 | Lyn Baranowski | Chief Executive Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-04-28 | Kathryn Haviland | Independent Director | Other Derivative Acquisition | +26,978 | $18.00 |
| 2026-04-28 | Kathryn Haviland | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-04-28 | Jon Congleton | Independent Director | Other Derivative Acquisition | +26,978 | $18.00 |
| 2026-04-28 | Jon Congleton | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-04-28 | Erin Lavelle | Independent Director | Initial Statement of Beneficial | 0 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
Avalyn 药 讨论区 0 条评论